A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)

The purpose of this study is to study the efficacy and safety of an investigational agent, GDC-085. The study drug will be administered orally to patients with relapsed or refractory NHL that has progressed despite standard of care therapy and for which there is no alternative therapy of proven benefit.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : ABT-199

Phase: Phase 2

Eligibility

Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

1. Histological or cytological confirmation of relapsed or refractory AML (by World Health Organization (WHO) classification) or untreated AML in patients who are unfit for intensive therapy. 2. Subject has an Eastern Cooperative Oncology Group (ECOG) Performance score of 0 to 2. 3. Subject must have adequate renal function as demonstrated by a calculated creatinine clearance ? 50 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft Gault formula using ideal body mass (IBM) instead of mass. 4. Subject must have adequate liver function.

External Links

Explore related trials

Contact information

Primary Contact:

Jack Taw 650-723-2781

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: